bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2025.04.22.649919

Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms

Halim, J.·Keane, A. P.·Bouzo, J.·Aderibigbe, T.·Chicola, J. A.·Nolan, K. T.·Jonnalgadda, K.·Tran, J. X.·Carabetta, V.
View original source ↗Export metadata ↓

Abstract

Acinetobacter baumannii is a nosocomial pathogen notorious for rapidly acquiring resistance to nearly all antibiotics, including last-line agents. Cefiderocol (FDC) is a novel siderophore cephalosporin antibiotic with in vitro activity against A. baumannii that is now used clinically, but resistance is emerging. There is limited data regarding FDC-containing antibiotic combinations with synergistic activity against A. baumannii, which may increase the potency of the drug and reduce resistance development. In this study, we evaluated the activity of FDC alone and in combination with other antibiotics against 21 extensively drug-resistant (XDR) and pandrug-resistant (PDR) A. baumannii clinical isolates. FDC possesses strong in vitro activity and was highly effective in combination with ceftazidime-avibactam (CAZ-AVI) and sulbactam-durlobactam (SUL-DUR), as well as amikacin, doxycycline, and sulbactam. We also identified several FDC-containing combinations effective against a metallo-{beta}-lactamase (MBL)-producing strain. Previously, we performed whole genome sequencing on selected strains in our collection, allowing for the identification of resistance genes and mechanisms associated with susceptibility patterns and synergy outcomes. These findings highlight promising FDC-based combinations for treating highly drug-resistant A. baumannii infections and provide insight into the genetic basis of FDC resistance and response. Author SummaryAcinetobacter baumannii is a frequent cause of hospital-acquired pneumonia, and bloodstream and wound infections in vulnerable populations, such as those who are critically ill or immunocompromised. Infections caused by A. baumannii are a growing problem in hospitals around the world, especially because of increasing resistance to almost all available antibiotics. Physicians have few treatment options available, which leads to high mortality rates. One newer antibiotic, cefiderocol, has shown promise against these infections, but resistance to this drug is already emerging. In our study, we looked for combinations of cefiderocol with other traditional and newly available antibiotics that work better together than alone. We tested these combinations against over 20 highly drug-resistant strains isolated from patients, including one strain that produces a strong resistance enzyme called NDM-1. We found that pairing cefiderocol with certain drugs, especially ceftazidime-avibactam, sulbactam-durlobactam, amikacin, and doxycycline, often worked significantly better than using cefiderocol alone. These combinations were able to prevent the growth of even the most resistant strains in our collection. Our work highlights new potential treatment options that physicians may use in the future to help patients with these dangerous, life-threatening infections, especially when standard antibiotics are no longer effective.

Source connections

Explore related subjects

microbiologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Halim, J., Keane, A. P., Bouzo, J., Aderibigbe, T., Chicola, J. A., Nolan, K. T., Jonnalgadda, K., Tran, J. X., Carabetta, V.. 2025-04-22. Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms. https://doi.org/10.1101/2025.04.22.649919

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

A conserved cysteine-histidine-glutamate metal site identifies DUF501 (Rv1025), an essential uncharacterised protein family of Mycobacterium tuberculosis, as a candidate metalloenzyme and drug target

A substantial fraction of the Mycobacterium tuberculosis proteome remains functionally uncharacterised. Rv1025, a 155-residue protein carrying the domain of unknown function DUF501 (Pfam PF04417), is essential by transposon mutagenesis and vulnerable by CRISPR interference, an attractive but neglected drug target, yet has never been functionally described. The family (4,370 proteins, no Gene Ontology term, no solved structure) is uncharacterised across all organisms and essential in three Actinobacterial genera. A Foldseek search of the AlphaFold model against complete structural databases finds no significant homolog, indicating a novel fold. The operon eno-divIC-Rv1025-ppx2 is conserved across the Actinobacteria phylum, yet AlphaFold-Multimer finds no direct complex between Rv1025 and its neighbour DivIC. Instead, conservation across 8,700 homologous sequences reveals a near-invariant Cys113-His115-Glu59 cluster forming a pocket. Holo AlphaFold3 predictions with Zn, Fe and Mn confidently place a divalent metal on this triad at 2.25-2.47 A; mutating the triad relocates the metal, and an independent backbone-geometry predictor recovers the same site, confirming specificity. The triad is universal across the family: present in all 1,472 near-complete bacterial sequences of the Pfam alignment, with no non-conservative substitution among the 2,228 sequences examined, a defining feature of bacterial DUF501 rather than a mycobacterial peculiarity. We propose that DUF501 is a metal-binding protein and candidate metalloenzyme, the first functional hypothesis for this family, whose conserved, essential metal pocket is a promising drug target. As the predictions build on a conservation-defined site within a fully computational study, they are supportive rather than proof of metal occupancy and warrant experimental validation.

microbiology↗
bioRxiv2026

Mycoplasmal endosymbionts of Trichomonas vaginalis are associated with reduced risk for Chlamydia trachomatis endometrial infection in asymptomatic, coinfected, women.

Trichomonas vaginalis is a protozoan parasite that causes trichomoniasis, the most common curable non-viral sexually transmitted infection, and Chlamydia trachomatis is a bacterial pathogen that can ascend to the upper genital tract and cause pelvic inflammatory disease, infertility, and ectopic pregnancy. T. vaginalis harbors bacterial endosymbionts, including Candidatus Malacoplasma girerdii, an obligate symbiont, and Metamycoplasma hominis, which can live freely or symbiotically. In a 16S rRNA sequencing study of the cervicovaginal microbiome of women at high risk for chlamydial infection, Ca. M. girerdii abundance was one of 13 features predicting lack of chlamydial spread to the endometrium, despite no direct association between T. vaginalis infection and reduced chlamydial ascension. Investigating the relationship between these microorganisms further, we found that T. vaginalis vaginal abundance correlated positively with chlamydial burden in women whose infection was confined to the cervix, while a nonsignificant inverse relationship was seen in women with endometrial spread. Among participants with high chlamydial burden, Ca. M. girerdii was detected exclusively in women without endometrial infection. Both endosymbionts trended toward more frequent detection, and higher abundance, in coinfected women without endometrial spread, while M. hominis abundance correlated strongly with T. vaginalis burden in this group. These findings suggest that mycoplasmal endosymbionts of T. vaginalis, rather than T. vaginalis itself, are microbial factors limiting chlamydial ascension, and point to a three-way interaction between parasite, endosymbiont, and bacterial pathogen that shapes upper genital tract C. trachomatis infection risk.

microbiology↗
bioRxiv2026

Understanding the physiological alterations of Vibrio cholerae upon exposure to L-ascorbic acid

The scourge of cholera remains a major global public health threat. It affects up to 4 million people worldwide and causes tens of thousands of deaths each year. The disease is experiencing a concerning resurgence in many parts of Africa, the Middle East, and Asia. To effectively tackle cholera and circumvent rising antimicrobial resistance, targeted biological and preventive approaches, complementing traditional rehydration, are urgently needed. In this regard, our group has demonstrated the efficacy of L-ascorbic acid in controlling the growth and pathogenesis of Vibrio cholerae in vitro. The present work further provides a mechanistic elucidation of the L-ascorbic acid-mediated physiological changes in V. cholerae and also bolsters such a non-antibiotic approach to control cholera.

microbiology↗